Last reviewed · How we verify
ADVM-022
ADVM-022 is an adeno-associated virus (AAV) vector-based gene therapy that targets the vascular endothelial growth factor A (VEGF-A) gene.
ADVM-022 is an adeno-associated virus (AAV) vector-based gene therapy that targets the vascular endothelial growth factor A (VEGF-A) gene. Used for Wet age-related macular degeneration.
At a glance
| Generic name | ADVM-022 |
|---|---|
| Also known as | AAV.7m8-aflibercept |
| Sponsor | Adverum Biotechnologies, Inc. |
| Drug class | AAV vector-based gene therapy |
| Target | VEGF-A |
| Modality | Biologic |
| Therapeutic area | Ophthalmology |
| Phase | Phase 2 |
Mechanism of action
By targeting the VEGF-A gene, ADVM-022 aims to reduce the expression of VEGF-A protein, which is involved in the formation of new blood vessels. This approach is intended to treat diseases characterized by abnormal angiogenesis, such as wet age-related macular degeneration.
Approved indications
- Wet age-related macular degeneration
Common side effects
- Increased intraocular pressure
Key clinical trials
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) (PHASE3)
- Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
- Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (PHASE3)
- Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA] (PHASE2)
- ADVM-022 Intravitreal Gene Therapy for DME (PHASE2)
- Long-Term Follow-up Study of ADVM-022 in DME (INFINITY-EXT)
- ADVM-022 Intravitreal Gene Therapy for Wet AMD (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |